welcome
CNBC

CNBC

Health

Health

Eli Lilly aims to invest in 'big problems hiding in plain sight' using obesity windfall

CNBC
Summary
Nutrition label

73% Informative

Eli Lilly's GLP-1 drugs Mounjaro and Zepbound are transforming the company.

Lilly is already testing its drug Kisunla for Alzheimer 's prevention.

The company's stock price has rocketed 268% higher in the last three years , giving the company a market cap of $823 billion .

VR Score

81

Informative language

85

Neutral language

47

Article tone

informal

Language

English

Language complexity

44

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

medium-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links